ArticleCancer cell2022
Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 46 citations in OpenAlex.
- Comparing infectious risk of Trastuzumab-deruxtecan to Trastuzumab-emtansine in patients with breast cancer.Breast cancer research and treatment · 2026Article
- COVID-19 Infection Confirmed by Bronchoalveolar Lavage Fluid Metagenomics -Next-Generation Sequencing Instead of Pharyngeal Swabs in Follicular Lymphoma: Three-Case Report and Literature Review.Journal of clinical laboratory analysis · 2025Review
- Article
- Dysregulated Adaptive Immune Responses to SARS-CoV-2 in Immunocompromised Individuals.Microorganisms · 2025Article
- Clinical Characteristics and Treatment Efficacy in Patients With SARS-CoV-2 Positivity After Nirmatrelvir-Ritonavir Therapy.Journal of medical virology · 2025Article
- Host Tissue Factors Predict Immune Surveillance and Therapeutic Outcomes in Gastric Cancer.Cancer immunology research · 2025Article
- Core features and inherent diversity of post-acute infection syndromes.Frontiers in immunology · 2025Review
- Case Report: Decentralized trial of tolerability-adapted exercise therapy after severe Covid-19.Frontiers in immunology · 2025Article
- The contributions of T cell-mediated immunity to protection from vaccine-preventable diseases: A primer.Human vaccines & immunotherapeutics · 2024Review
- Machine learning based predictive modeling and risk factors for prolonged SARS-CoV-2 shedding.Journal of translational medicine · 2024Article
- Article
- Long-Term Outcomes of COVID-19 and Risk Factors for Prolonged or Persistent COVID-19 in Lymphoma Patients: A Multicenter, Retrospective Cohort Study.Journal of Korean medical science · 2024Article
- A Robust Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific T- and B-Cell Response Is Associated With Early Viral Clearance in SARS-CoV-2 Omicron-Infected Immunocompromised Individuals.The Journal of infectious diseases · 2024Article
- Article
- Immunophenotype of lymphocytes and real-world outcome of COVID-19 infection in children with hematology and oncology.BMC cancer · 2024Article
- Prolonged viral pneumonia and high mortality in COVID-19 patients on anti-CD20 monoclonal antibody therapy.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- The role of SARS-CoV-2 nucleocapsid protein in antiviral immunity and vaccine development.Emerging microbes & infections · 2023Article
- Clinical experience in the treatment of COVID-19 with monoclonal antibodies in solid organ transplant recipients.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023Review
- Predictive factors of delayed viral clearance of asymptomatic Omicron-related COVID-19 screened positive in patients with cancer receiving active anticancer treatment.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023Article
- Coronavirus Disease-2019 in the Immunocompromised Host.Clinics in chest medicine · 2023Review
Corrections and comments
- Commented on byCD82022
Authors and funding
20 authors at 4 institutions in 1 country.
Olga LyudovykComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Justin Y KimDivision of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
David QuallsLymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Madeline A HweeHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ya-Hui LinHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sawsan R BoutemineDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yuval ElhanatiComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alexander SolovyovComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Melanie DouglasLymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Eunise ChenUniversity of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.
N Esther BabadyInfectious Diseases Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Clinical Microbiology Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lakshmi RamanathanClinical Chemistry Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Pallavi VedantamMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Chaitanya BandlamudiMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Sigrid GoumaDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Philip WongMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Scott E HensleyInstitute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Benjamin GreenbaumComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Physiology, Biophysics & Systems Biology, Weill Cornell Medicine, Weill Cornell Medical College, New York, NY, USA. Electronic address: greenbab@mskcc.org.
Alexander C HuangDivision of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. Electronic address: alexander.huang@pennmedicine.upenn.edu.
Santosha A VardhanaLymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. Electronic address: vardhans@mskcc.org.
Memorial Sloan Kettering Cancer Center · USUniversity of Pennsylvania · USParker Institute for Cancer Immunotherapy · USThe University of Texas Health Science Center at Houston · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MA Statistical Physics Framework for Understanding the Role of Repeat RNA in Tumor ImmunityU01CA228963 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI GREENBAUM, BENJAMIN, TING, DAVID TSAI · 2020 to 2024
$3.2MRole of tumor burden in limiting durable reinvigoration by PD-1 blockadeK08CA230157 · NCI · UNIVERSITY OF PENNSYLVANIA · PI HUANG, ALEXANDER · 2019 to 2023
$1.0MNCI NIH HHS K08 CA230157NCI NIH HHS P30 CA008748NCI NIH HHS U01 CA228963
Abstract
How immune dysregulation affects recovery from COVID-19 infection in patients with cancer remains unclear. We analyzed cellular and humoral immune responses in 103 patients with prior COVID-19 infection, more than 20% of whom had delayed viral clearance. Delayed clearance was associated with loss of antibodies to nucleocapsid and spike proteins with a compensatory increase in functional T cell responses. High-dimensional analysis of peripheral blood samples demonstrated increased CD8
Indexed as
COVID-19CD4-Positive T-LymphocytesCD8-Positive T-LymphocytesHumansImmunity, CellularImmunity, HumoralImmunologic MemoryReceptors, Antigen, T-CellSARS-CoV-2Receptors, Antigen, T-CellcancerCD20convalescentCOVID-19rituximabSARS-CoV-2T cell
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.